{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T02:15:42Z","timestamp":1788833742996,"version":"build-2803163510"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T00:00:00Z","timestamp":1772409600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The clonal evolution from a diffuse large B-cell lymphoma (DLBCL) to a plasmablastic lymphoma (PBL) is uncommon, presenting remarkable clinical challenges. This phenomenon has critical diagnostic and therapeutic implications, particularly in cases of EBV-negative lesions that show immunophenotypic divergence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case summary<\/jats:title>\n                    <jats:p>We herein report an unusual case of two different immunophenotypes, namely DLBCL in the porta hepatis and concomitant PBL in the stomach. Immunoglobulin gene rearrangement analysis confirmed that the two tumors had the same clonal origin. The patient presented with characteristic PBL features, including loss of CD20 expression, high MYC expression, co-expression of BCL2, and a distinctive clinical manifestation involving gastric mucosa. The patient demonstrated only a transient response to initial therapy with R-CHOP plus bortezomib, following which she had rapid disease progression, resulting in an overall survival of 10 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>For extranodal lymphomas, multisite sampling should be performed for a confirmed diagnosis to prevent misdiagnosis or oversight of concurrent lesions. This diagnostically challenging case highlights the importance of molecular testing for identifying and understanding the clonal evolution of lymphomas and suggests how immunophenotypic heterogeneity may lead to misdiagnosis. It also provides important insights into the biology of DLBCL-to-PBL evolution. These findings highlight the need for more precise molecular diagnostic tools and novel approaches to improve outcomes for patients with such highly aggressive lymphoma.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1784860","type":"journal-article","created":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T05:20:50Z","timestamp":1772428850000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Case Report: Clonal evolution of diffuse large B-cell lymphoma to plasmablastic lymphoma: diagnostic challenges in a case of gastric lesion with EBV-negative PBL"],"prefix":"10.3389","volume":"16","author":[{"given":"Jie","family":"Xu","sequence":"first","affiliation":[{"name":"Department of Hematology, Affiliated Hospital of Shandong University of Traditional Chinese Medicine","place":["Jinan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueli","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Affiliated Hospital of Shandong University of Traditional Chinese Medicine","place":["Jinan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Feng","sequence":"additional","affiliation":[{"name":"Department of Pathology, Affiliated Hospital of Shandong University of Traditional Chinese Medicine","place":["Jinan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dejie","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Vascular Surgery, Affiliated Hospital of Shandong University of Traditional Chinese Medicine","place":["Jinan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kui","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Affiliated Hospital of Shandong University of Traditional Chinese Medicine","place":["Jinan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyuan","family":"Cui","sequence":"additional","affiliation":[{"name":"Department of Hematology, Affiliated Hospital of Shandong University of Traditional Chinese Medicine","place":["Jinan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Affiliated Hospital of Shandong University of Traditional Chinese Medicine","place":["Jinan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.2174\/1568009620666210106122750","article-title":"Epigenetic mechanisms of therapy resistance in diffuse large B cell lymphoma (DLBCL)","volume":"21","author":"Isshiki","year":"2021","journal-title":"Curr Cancer Drug Targets"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S326632","article-title":"Diffuse large B-cell lymphoma (DLBCL): early patient management and emerging treatment options","volume":"15","author":"Vodicka","year":"2022","journal-title":"Onco Targets Ther"},{"key":"B3","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/ijlh.13863","article-title":"Plasmablastic lymphoma: an update","volume":"44","author":"Bailly","year":"2022","journal-title":"Int J Lab Hematol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-021-03211-w","article-title":"Heterogeneity in the diagnosis of plasmablastic lymphoma, plasmablastic myeloma, and plasmablastic neoplasm: a scoping review","volume":"114","author":"Mori","year":"2021","journal-title":"Int J Hematol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1159\/000475530","article-title":"Tumor heterogeneity in lymphomas: a different breed","volume":"85","author":"Sch\u00fcrch","year":"2018","journal-title":"Pathobiology"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023010412","article-title":"A significant proportion of classic Hodgkin lymphoma recurrences represents clonally unrelated second primary lymphoma","volume":"7","author":"Van Bladel","year":"2023","journal-title":"Blood Adv"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.7754\/clin.lab.2021.211028","article-title":"Disparity analysis of clinicopathologic hallmarks between transformed DLBCL and primary DLBCL","volume":"68","author":"Sun","year":"2022","journal-title":"Clin Lab"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.plabm.2020.e00191","article-title":"Validation and interpretation of IGH and TCR clonality testing by Ion Torrent S5 NGS for diagnosis and disease monitoring in B and T cell cancers","volume":"22","author":"Lay","year":"2020","journal-title":"Pract Lab Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1155\/2024\/4803071","article-title":"EBV positive diffuse large B cell lymphoma with negative pan-B cell markers: case report and literature review","volume":"2024","author":"Shold","year":"2024","journal-title":"Case Rep Hematol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1097\/PAP.0000000000000253","article-title":"Lymphoid neoplasms with plasmablastic differentiation: a comprehensive review and diagnostic approaches","volume":"27","author":"Chen","year":"2020","journal-title":"Adv Anat Pathol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2021-0462-OA","article-title":"CD138\u2013 plasmablastic lymphoma: a multi-institutional study and review of the literature","volume":"147","author":"Choudhuri","year":"2023","journal-title":"Arch Pathol Lab Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.4132\/jptm.2024.05.14","article-title":"Concurrent intestinal plasmablastic lymphoma and diffuse large B-cell lymphoma with a clonal relationship: a case report and literature review","volume":"58","author":"Imuta","year":"2024","journal-title":"J Pathol Transl Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/8876567","article-title":"Clonally related plasmablastic lymphoma simultaneously occurring with diffuse large B-cell lymphoma","volume":"2020","author":"Hashimoto","year":"2020","journal-title":"Case Rep Hematol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1002\/ajh.24375","article-title":"Transformation of a previously diagnosed diffuse large B-cell lymphoma to plasmablastic lymphoma","volume":"91","author":"Marini","year":"2016","journal-title":"Am J Hematol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1101\/2020.04.12.038414","article-title":"Co-activation of NF-\u03baB and MYC renders cancer cells addicted to IL6 for survival and phenotypic stability","author":"Barbosa","year":"2020","journal-title":"bioRxiv"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-0716-1669-7_20","article-title":"Generation and surgical analysis of genetic mouse models to study NF-\u03baB-driven pathogenesis of diffuse large B cell lymphoma","volume":"2366","author":"Maybury","year":"2021","journal-title":"Methods Mol Biol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/modpathol.2016.162","article-title":"Plasmablastic lymphoma phenotype is determined by genetic alterations in MYC and PRDM1","volume":"30","author":"Montes-Moreno","year":"2017","journal-title":"Mod Pathol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/srep12168","article-title":"Epstein-Barr virus positive diffuse large B-cell lymphoma predict poor outcome, regardless of the age","volume":"5","author":"Lu","year":"2015","journal-title":"Sci Rep"},{"key":"B19","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s13045-015-0163-z","article-title":"Stage, age, and EBV status impact outcomes of plasmablastic lymphoma patients: a clinicopathologic analysis of 61 patients","volume":"8","author":"Loghavi","year":"2015","journal-title":"J Hematol Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023021348","article-title":"The influence of immunodeficiency, disease features, and patient characteristics on survival in plasmablastic lymphoma","volume":"143","author":"Di Ciaccio","year":"2024","journal-title":"Blood"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3884","article-title":"Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma","volume":"21","author":"Wilson","year":"2015","journal-title":"Nat Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1311846111","article-title":"High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B cell lymphoma cells","volume":"111","author":"Mathews Griner","year":"2014","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.090597","article-title":"Rituximab plus gemcitabine and oxaliplatin in patients with refractory\/relapsed diffuse large B cell Lymphoma who are not candidates for high-dose therapy. A phase II lymphoma study association trial","volume":"98","author":"Mounier","year":"2013","journal-title":"Haematologica"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-02-636316","article-title":"Approach to the diagnosis and treatment of High-grade B-cell lymphomas with myc and bcl2 and\/or bcl6 rearrangements","volume":"129","author":"Sesques","year":"2017","journal-title":"Blood"},{"key":"B25","doi-asserted-by":"publisher","first-page":"e2024015","DOI":"10.4084\/MJHID.2024.015","article-title":"Plasmablastic lymphoma. A state-of-the-art review: part 2-focus on therapy","volume":"16","author":"Bibas","year":"2024","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1697566","article-title":"Case report: CD19 and CD22 CAR-T therapy induced durable complete remission in a patient with refractory plasmablastic lymphoma","volume":"16","author":"Liu","year":"2025","journal-title":"Front Immunol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1784860\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T05:20:52Z","timestamp":1772428852000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1784860\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,2]]},"references-count":26,"alternative-id":["10.3389\/fonc.2026.1784860"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1784860","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,2]]},"article-number":"1784860"}}